Common GLP-1 side effects include nausea (40-44%), diarrhea (29-33%), vomiting (24-25%), and constipation (21-24%)
The study involved 411 adult patients with T2DM and was designed as a randomized, double-blind, placebo-controlled trial where patients received varying doses of danuglipron or a placebo
Studies were identified through search of trial registries and databases (Medline, Embase, PsycINFO, CINAHL, Cochrane, Web of Science) from inception through February 2025 for randomized controlled trials, nonrandomized comparative trials, and observational studies
& Benahmed, M
The MMRM includes treatment group, gender, country, visit and visit-by-treatment as fixed effects and baseline value as covariate